Mergers & Acquisitions Mergers & Acquisitions

Hypera tells CADE pandemic hasn't affected deal with Boehringer

By Ana Paula Candil
  • 20 Jul 2020 17:14
  • 20 Jul 2020 17:40
Hypera has told the Brazilian competition authority that the pandemic hasn't affected its plans to buy and invest in Boehringer Ingelheim's antispasmodics and analgesics brands, but "reinforced" the need to "urgently" close the transaction, which involves the acquisition of a medicine that relieves symptoms of Covid-19. 

Hypera is planning to buy Boehringer Ingelheim's

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Ana Paula Candil

Senior Correspondent, Latin America


Ana Paula joined MLex in Brazil in 2014 writing about antitrust investigations and merger reviews. Prior to that, she worked for several trade publications and in TV. She lived in Washington DC, where she worked for Al Jazeera English in 2010. She studied journalism and holds a postgraduate diploma in International Business Management from the George Brown College in Toronto and a Master of Business Administration diploma in government relations from Fundação Getúlio Vargas (FGV).

Discover MLex

Stay on top of global regulatory developments

TAKE A FREE TRIAL

Latest News